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The role of non-steroidal anti-inflammatory drugs in inflammatory bowel disease is controversial, as they have been implicated
in disease aggravation. Different from other cyclooxygenase inhibitors, acetylsalicylic acid (ASA) enhances the formation of anti-
inflammatory and proresolution lipoxins derived from arachidonic acid as well as resolvins from omega-3 polyunsaturated fatty
acids such as docosahexaenoic acid (DHA). In this study, we examined the effect of ASA on murine dextran sodium sulfate colitis.
A mouse magnetic resonance imaging (MRI) protocol and post mortem assessment were used to assess disease severity, and
lipid metabolites were measured using liquid chromatography-coupled tandem mass spectrometry. Decreased colitis activity was
demonstratedbyphenotypeandMRIassessmentinmicetreatedwithASA,andconfirmedinpostmortemanalysis.Analysisoflipid
mediatorsshowedsustainedformationoflipoxinA4andanincreaseofDHA-derived17-hydroxydocosahexaenoicacid(17-HDHA)
after treatment with ASA. Furthermore, in vitro experiments in RAW264.7 murine macrophages demonstrated significantly
increased phagocytosis activity after incubation with 17-HDHA, supporting its proresolution effect. These results show a protective
effect of ASA in a murine colitis model and could give a rationale for a careful reassessment of ASA therapy in patients with
inflammatory bowel disease and particularly ulcerative colitis, possibly combined with DHA supplementation.
1. Introduction
The inflammatory bowel diseases (IBDs) ulcerative colitis
(UC),confinedtothecolon,andCrohn’sdisease(CD),affect-
ing the whole gastrointestinal tract, are chronic inflamma-
tory disorders with considerable morbidity and, particularly
for UC, mortality due to a high risk of colorectal cancer
development. Current therapy for IBD focuses on drugs
that inhibit inflammation [1–4]. Human data regarding the
potentialbenefitsandrisksofCOXinhibitioninpatientswith
IBD are conflicting [5–9] .Th i si sa l s or e fl e c t e di na n i m a l
studies examining COX inhibition in experimental colitis
models. While some recent studies found deleterious effects
inanimalswithDSScolitisassociatedwithinhibitionofCOX
[10–13], others demonstrated a benefit of COX-2 inhibitor
treatment [14, 15].
Recently, newly discovered lipid mediators have been
implicated in the alleviation of colitis [16]. The lipoxins are2 BioMed Research International
lipid mediators originating from the omega-6 polyunsatu-
rated fatty acid (n-6 PUFA) arachidonic acid (AA) by enzy-
maticactionofdifferentlipoxygenasesorbyacetylatedCOX-
2[ 17]. Studies have demonstrated potent anti-inflammatory
and inflammation dampening properties for lipoxins [18],
and stable analogues of lipoxins were shown to alleviate
experimental colitis [19, 20]. Similarly, protective lipid medi-
ators (so-called resolvins) can be formed from omega-3
polyunsaturated fatty acids (n-3 PUFAs) such as eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA). Our
previous work demonstrated formation of resolvins in mice
with increased omega-3 fatty acid tissue content in the
context of DSS colitis [21] ,a n do t h e rs t u d i e sh a v es h o w na n
anti-inflammatoryeffectofseveralofthesecompoundsinthe
context of experimental colitis models [22–24].
In this study, we analyzed the effect of acetylsalicylic acid
(ASA) in chemically induced acute DSS colitis in mice. DSS
colitis is characterized by initial injury to the epithelial cells
followed by inflammation and has been shown to be a good
model to test therapeutics for human inflammatory bowel
disease[25].Manystudieshaveusedthismodelinthepastas
itisregardedasagoodanimalmodelofIBD,andparticularly
UC, with a predominant site of inflammation in the distal
colon [26].
To evaluate disease activity in the different groups, we
extended our analysis beyond the conventional phenotype
and morphology markers and employed small animal MRI
technology. Noninvasive imaging in murine models of colitis
has been previously described using CT and MRI technolo-
gies [27–29]. For the study presented here, a modified pro-
tocol was devised in order to reliably measure and compare
colon wall thickness and hyperemia in different mice.
To assess possible mechanisms responsible for the
observed protection in ASA-treated mice, mass spectro-
metric measurements were then employed to determine
hydroxylated lipid metabolites and mediators derived from
AA (lipoxin A4 and 15-epi-lipoxin A4) and from 17-hydroxy-
docosahex-aen-o-ic acid (DHA).
2. Materials and Methods
2.1.InductionofColitis. FemaleC57BL/6micewereobtained
fromCharlesRiverLaboratories(Wilmington,MA)andheld
until the desired age (6 weeks) and body weight (19–21g).
For testing of different treatment regimens, mice were
divided into 3 groups. One group received 3% DSS dissolved
in sterile drinking water and daily intraperitoneal (ip) injec-
tions of 0.5mg acetylsalicylic acid (ASA, Sigma-Aldrich, St.
Louis, MO) dissolved in 300𝜇L of vehicle (3.33% EtOH in
0.9% NaCl) for 5 days (𝑛=5 ). Another group received 3%
DSSaswellasipinjectionsofthevehiclealonefor5days(𝑛=
6). Finally, the last group received sterile drinking water and
ip injection of vehicle alone and served as a control (𝑛=3 ).
ThefirstipinjectionofASAorvehiclewasadministeredright
before the mice were switched to DSS-containing drinking
water. After 5 days, the DSS-containing water was replaced
with sterile drinking water.
2.2. Evaluation of Colitis Severity. Body weight measurement
(presented as percentage of body weight on day 0) as well as
evaluation of stool status was carried out daily. Stool samples
from individual mice were evaluated on a three-point scale
u s i n gat e s tf o ro c c u l tb l o o d( H e m o c c u l t ,B e c k m a nC o u l t e r
Inc., Fullerton, CA) as well as macroscopic evaluation (0 =
no occult blood; 1 = test for occult blood slightly positive;
2=t e s tf o ro c c u l tb l o o ds t r o n g l yp o s i t i v e ;a n d3=b l o o d y
stool). On day 9, mice were sacrificed, colons were excised,
a n dl e n g t hw a sm e a s u r e d .A l ls a m p l e sw e r es n a pf r o z e ni n
l i q u i dn i t r o g e na n ds t o r e da t−80
∘C for further analysis.
2.3. Histological Evaluation. Frozen tissue sections from the
distal colon of all mice were mounted in OCT medium.
Sections were cut at 5𝜇mt h i c k n e s sa n dm o u n t e do ng l a s s
slides. After air drying, sections were fixed in fixing medium
(70% ethanol, 4% formaldehyde, and 5% glacial acetic acid
in H2O), washed in ethanol (70%) and water, followed by
standard hematoxylin and eosin stain. Slides were evaluated
in a blinded manner and scored according to severity of
inflammation (0 = no inflammation, 1 = mild, 2 = moderate,
and 3 = severe), thickness of inflammatory involvement (0 =
no inflammation, 1 = mucosa, 2 = mucosa plus submucosa,
and 3 = transmural), character of epithelial damage (0 =
intact epithelium, 1 = disruption of architectural structure, 2
= erosion, and 3 = ulceration), and extent of lesions (0 = no
lesions, 1 = punctuate, 2 = multifocal, and 3 = diffuse). This
evaluationprotocolisbasedonapreviouslydescribedscoring
system for DSS colitis [30].
2.4. Magnetic Resonance Imaging (MRI). Mice were scanned
on day 3 and day 8 of the experimental protocol. MRI
assessment of colitis was performed using a Bruker 4.7T
Avance horizontal bore system (Bruker Avance, Karlsruhe,
Germany) equipped with a 200mm gradient set capable of
30G/cm gradient strength. During the MR scan, the mice
were mounted on a home-built nonmagnetic holding bar
equipped with a nose cone for anesthesia delivery and were
anaesthetized using 1.5%–2% (vol/vol) isoflurane (Baxter,
Deerfield, IL) in 1L/min oxygen flow. The breathing rate of
the mice was monitored using a small animal monitoring
a n dg a t i n gs y s t e m( S m a l lA n i m a lI n s t r u m e n t sI n c . ,N Y ) .Th e
isofluraneflowwasadjustedtoachieveabreathingrateof20–
30 breaths per minute during the scanning process. In order
to standardize the comparisons of wall thickness as well as
colon wall signal intensity between different animals, a non-
magnetic (plastic) tube (outer diameter 2.1mm) was placed
approximately 9mm into the rectum of the anaesthetized
mice (Figure 1(a)). For each mouse, 24 T2 weighted 2D axial
images were acquired to cover the colon using a fast spin
echo sequence with a repetition time (TR) of 2683ms, an
echo time (TE) of 12ms, a 128 × 128 matrix, and a 3.0cm
× 3.0cm field of view (FOV). The slice thickness was set
to 1mm, and the number of averages was 8. After image
acquisition, the plastic tube was removed, and the animals
were transferred to a heating pad until they were fully awake.
The images were analyzed using standard imaging software
(Adobe Photoshop, Adobe Systems, San Jose, CA).BioMed Research International 3
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Figure 1: MRI analysis of colitis severity. (a) For MRI analysis of disease severity, a plastic tube with outer diameter of 2.1mm was carefully
placed approximately 9mm into the rectum of the anaesthetized mouse. (b) Analysis was performed by comparing wall thickness as well as
brightness between the different mice in three defined slices.
C o l o nw a l lt h i c k n e s sw a st h e nm e a s u r e do nt h eT 2
weighted images from three slices of the distal colon with a
standardized distance of 3mm between slices (Figure 1(b)).
For each slice, three measurements were performed, and the
means for each animal were calculated. For signal intensity
analysis, a region of interest (ROI) was drawn within the
colon wall. A histogram tool was used to analyze the bright-
ness of the pixels within the ROI. This was repeated for the
same three slices that were used for the wall thickness mea-
surements.Thepixelbrightnessmeanswerethennormalized
bycomparisonwiththenearbyfattytissuearoundtheovaries
of the mice.
2.5. Lipid Metabolite Analysis. 30mg ground and frozen
c o l o nt i s s u ew a sm i x e dw i t h5 0 0 𝜇Lw a t e ra n d5 0 0 𝜇L
methanol, internal standard consisting of 10ng LTB4-d4 was
added, and the sample was then hydrolyzed with 300𝜇L
of 10M sodium hydroxide for 30 minutes at 60
∘C. The
solution was neutralized with 60% acetic acid, and the pH
was adjusted to 6.0 with sodium acetate buffer. A solid phase4 BioMed Research International
extraction was performed as previously described [31]. For
elution,ann-hexane:ethylacetateextractionmixture(25:75)
with 1% acetic acid was used. The eluate was evaporated
on a heating block at 40
∘C under a stream of nitrogen
to obtain a solid residue. Residues were then dissolved
in 70𝜇L acetonitrile and measured using an Agilent 1200
H P L Cs y s t e mc o u p l e dt oa nA g i l e n t6 4 1 0T r i p l eq u a dm a s s
spectrometerwithanelectrosprayionizationsource.Analysis
of lipid metabolites was performed with multiple reaction
monitoring in negative mode.
2.6. Phagocytosis Assay. RAW 264.7 cells were grown in
Dulbecco’smodifiedEagle’smedium(DMEM)supplemented
with 10% fetal bovine serum, 100U/mL penicillin, and
100U/mL streptomycin. All experiments were performed in
a humidified atmosphere under 5% CO2 at 37
∘C. Cells were
plated in 96-well plates at a density of 1 × 10
5 cells/well and
incubated overnight. To quantify phagocytosis, cells were
incubated with fluorescein-labelled bioparticles (Vybrant
Phagocytosis Assay, Invitrogen, Carlsbad, CA), diluted 1:2.
Uptake was measured after 4h in a fluorescence plate reader,
essentially following the manufacturer’s protocol. To evaluate
the effect of 17-HDHA on phagocytosis, cells were pretreated
with1𝜇M17-HDHAfor2h.Positivecontrolswithequivalent
volumes of ethanol (vehicle) and negative controls were
performed in parallel.
2.7. Statistical Analysis. Statistical analysis was performed
with GraphPad Prism 3.02v Software (GraphPad, La Jolla,
CA). Comparison was made using the Mann-Whitney U test
or as indicated. All values are presented as the mean ± SEM.
Statistical significance was set at 𝑃 < 0.05.
3. Results
Induction of colitis resulted in marked changes in body
weight, appearance of fecal blood, and general status. Mice
treated with ASA showed significantly less body weight loss
(Figure 2(a)) as well as a recovery of body weight within 3
days after the end of DSS exposure, while untreated mice
exhibited only a stabilization of body weight after cessation
of DSS.
Colitis disease activity was evaluated by MRI on day 3
and day 8 of the treatment protocol. The MRI results show a
marked difference between the treated groups of mice with
less wall thickness and a significantly lower T2 weighted
signal intensity (brightness) in the mice treated with ASA, as
signs of a lower inflammatory infiltration (Figure 2(b)). Due
to technical limitations in the number of MRI scans we were
abletoperform,only3animalspergroupwereassayed,which
does not give enough values for statistical normality testing
using, for example, the Kolmogorov-Smirnov test. Applying
nonparametric Mann-Whitney U testing to these data led
to nonsignificant findings. However, when hypothesizing
normal distribution—and thus applying Student’s t-test—for
these data, the differences for thickness as well as brightness
were significant on day 3 and day 8 with 𝑃 < 0.01 when
comparing the ASA + DSS group versus DSS alone.
The results of the MRI and body weight analyses con-
fi r m e dt h ed e c r e a s e dd i s e a s ea c t i v i t yi nt h em i c et r e a t e d
with ASA. Furthermore, assessment of bloody stools in the
animals showed a trend towards more severe and prolonged
bleedingintheDSSgroup(Figure 2(c)).However,conclusive
statistical evaluation of these data could not be performed, as
it was not possible to do stool testing on every animal every
day of the experimental protocol.
The in vivo disease activity assessments were validated
in the postmortem analysis of the colons, with wall thick-
nesses similar to those observed in the MRI measure-
ments (Figure 3(a)) and significantly less colon shortening in
mice treated with ASA as compared to mice exposed only
to DSS (Figure 3(b)). Microscopic grading of the changes
i nt h ec o l o nr e v e a l e dd e c r e a s e di n fl a m m a t o r ya c t i v i t yi n
m i c et r e a t e dw i t hA S A( s u m m a r i z e ds c o r e sa r es h o w ni n
Figure 3(c)).However,wewerenotabletodocumentchanges
in inflammatory activity biochemically, as serum TNF-𝗼
levels, measured by ELISA, were not significantly different
between the different treatment groups (data not shown).
As lipid mediators formation of AA-derived lipoxins
and n-3 PUFA-derived resolvins can be increased by ASA-
induced acetylation of the COX-2 enzyme [32], we assessed
several of these mediators and their precursors in the colons
of mice with DSS-induced colitis with and without treatment
with ASA. Due to the presence of AA and DHA but not
EPA in the colon tissue of the mice used in this study (data
not shown), we focused on the assessment of AA-derived
lipoxins and DHA-derived 17-hydroxydocosahexaenoic acid
(17-HDHA).LipoxinA4 and15-epi-lipoxinA4 concentrations
weredecreasedincolontissuefrommicethreedaysafterDSS
exposure,butformationof15-epi-lipoxinA4 wassignificantly
higher in mice treated with ASA as compared to the DSS
alonetreatmentgroup(Figures 4(a)and4(b)).Unexpectedly,
t h eD H A - m e t a b o l i t e1 7 - H D H Aw a ss i g n i fi c a n t l yh i g h e ri n
colon tissues from mice three days after DSS exposure
(Figure 4(c)) and was increased even more in tissue samples
from mice treated with ASA.
In order to further elucidate the mechanism by which
17-HDHA might contribute to inflammation dampening and
resolution, the in vitro ability of 17-HDHA to increase phago-
cytosiswastested.Intheseexperiments,anassaysystemwith
fluorescently labeled E. coli K - 1 2b i o p a r t i c l e sw a su s e da sa
tool to study overall phagocytotic activity of macrophages
[33, 34]. A significant (1.25-fold) increase in phagocytosis
activityafter1𝜇M17 -HDH ApreincubationintheRA W264.7
murinemacrophagecelllinewasdemonstrated(Figure 5(a)).
4. Discussion
The data presented here indicate that DSS-induced colon
inflammation can be alleviated by acetylsalicylic acid.
Although a number of previous studies have examined the
effectiveness of COX inhibitors in the context of DSS colitis,
theoutcomesofthesestudieswereinconsistentorconflicting
[10–15], and, to our knowledge, ASA was never used in
experimentalDSScolitis.ThismaybeduetothefactthatASA
causes ulcerations, erosions, and gastrointestinal bleeding in
t h es t o m a c ha sw e l la st h es m a l lb o w e l ,a n dm a n yc l i n i c i a n sBioMed Research International 5
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Figure 2: In vivo assessment of colitis severity. (a) Body weight course in the different groups, 𝑛=3for the control group, 𝑛=5for the
ASA-group, and 𝑛=6for the DSS group;
∗𝑃 < 0.05 versus DSS. (b) MRI-measured colon wall thickness and brightness on day 3 as well as
day 8 of the experimental protocol, 𝑛=3for each treatment group. In dashed lines, the values of measurements in untreated control mice
are shown. (c) Bleeding score evaluation in animals treated with DSS or ASA + DSS. There was no bleeding in control animals (not shown).6 BioMed Research International
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Figure 3: Postmortem assessment of colitis severity. (a) Hematoxylin and eosin stains of transmural colon walls. Representative images of
controltissueascomparedtoanimalstreatedwithDSSandASA+DSS.(b)Colonshorteningasanindicatorofdiseaseseveritywascompared
between the different experimental groups, 𝑛=5for the ASA-group and 𝑛=6for the DSS group;
∗𝑃 = 0.044 versus DSS. (c) Histological
grading score, 𝑛=5for the ASA-group and 𝑛=6for the DSS group;
ns𝑃 = 0.054 versus DSS. Untreated controls (not shown) reached a
maximum of 2 points in this score.
believe it therefore to be too GI toxic to be of any value in the
control of colonic inflammation.
A tthesa metime,pa tien tswi thIBD ,a ndpa rticula rlyUC,
remain at increased risk for colorectal cancer [35, 36]. Long-
term ASA treatment has been shown to be effective for colon
cancer prevention [37–40]. In patients with UC, although
datainthisfieldisscarce,asimilarriskreductionofcolorectal
cancercouldbeshown[41],arguingforASAusealsointhese
patients.
We set out to study the effect of ASA supplementation
on the course of DSS-induced colitis in mice, hypothesizing
an effect of aspirin treatment on the formation of hydroxy-
lated lipid mediators such as the lipoxins as well as DHA-
derivedcompounds.Thesewerecharacterizedaspotentanti-
inflammatorycompoundsalsointhecontextofDSScolitisin
previous studies [19, 23].
In our experiments, we aimed for an ASA dose compa-
rable to low-dose ASA administration in humans. Previously
publisheddataonlow-doseASAadministrationinmicewith
intestinal or other tumors used doses of 40mg/kg [42]a n d
50mg/kg [43]. High-dose ASA dosage was at 400mg/kg in
a previous tumor prevention study in mice [44]. Two studies
in intestinal tumor models used a dose of 25mg/kg [45, 46],
which the authors calculated to correspond to a dose of 80–
110mg/day in humans on a 2000kcal diet following nutrient
density calculations [47], and we decided to use this dose in
our experiment to mimic low-dose ASA administration. A
limitation of the data presented here is that no experiments
with ASA only treatment were performed. However, the
previous study by Mahmoud et al. has established the safety
of long-term administration of ASA at a dose of 25mg/kg in
mice [45].
In the study presented here, we found significant changes
in the tissue concentrations of anti-inflammatory lipoxins,
with suppression of lipoxin A4 and 15-epi-lipoxin A4 in the
mice with DSS colitis. As compared to this, the lipoxin
levels in the ASA-treated animals were higher, which could
contributetotheprotectionfromcolitisseenintheseanimals.
In contrast, the amount of the DHA-derived 17-HDHA
increased in animals after DSS treatment and even more so
with concomitant ASA treatment. While higher levels of 17-
HDHAwerepresentinthecolonsfrommiceafterDSScolitis
induction as compared to controls, the treatment with ASA
l e dt oe v e nh i g h e r1 7 - H D H At i s s u ec o n c e n t r a t i o n s .
17-HDHA is the precursor for the formation of anti-
inflammatory D resolvins, and several previous studies fromBioMed Research International 7
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Figure 4: Assessment of lipid mediators. Shown are the arachidonic acid-derived lipoxin A4 (a) and 15-epi-lipoxin A4 (b) with 𝑛=3for the
control group, 𝑛=5for both the DSS alone and the DSS plus ASA groups;
ns𝑃 = 0.056 versus DSS (not significant);
∗𝑃 = 0.016 versus DSS.
(c) The levels of 17-HDHA, with 𝑛=3for the control group, 𝑛=5for both the DSS alone and the DSS plus ASA groups;
∗𝑃 = 0.036 versus
controls;
∗∗𝑃 = 0.008 versus DSS (b).
other groups have demonstrated biological effects of the
different stereoisomers of this compound, as summarized
in (Figure 5(b)). It was shown that TNF-𝗼 secretion from
murine macrophages can be suppressed by 17S-HDHA [48].
Furthermore, it has been demonstrated that 17S-HDHA is
a precursor of the D(S)-resolvins, which are potent anti-
inflammatory mediators [49–51]. Similarly, the 17-HDHA
epimer 17R-HDHA as well as the D(R)-resolvins were
recently shown to be anti-inflammatory in the context of
experimental colitis, peritonitis, and arthritis [23, 51, 52].
The liquid chromatograph tandem mass spectrometry
(LC-MS/MS) setup used in the study presented here was not
abletodifferentiatebetweenthe17S-and17R-HDHAepimers
and could not reliably identify resolvin D1 in tissue samples.
However, as both epimers of 17-HDHA are precursors of
anti-inflammatory D-resolvins, the increase in total 17(R/S)-
HDHA observed in this study is an indicator of significantly
increased formation of these anti-inflammatory lipid media-
tors derived from DHA.
Indeed, our in vitro results presented previously showed
a 17-HDHA-triggered decrease in TNF-𝗼 secretion [53].
Together with the increased phagocytosis activity by 17-
H D H As h o w nh e r e( Figure 5), this indicates that a mix of
the 17R/S-HDHA epimers itself carries anti-inflammatory
activity.DataforlipoxinA4 [54,55]andresolvinD1[56]ha ve
establishedtheconceptofincreasedphagocytosisasamarker
of inflammation dampening and resolution. Therefore, the
d a t as h o w nh e r ef o r1 7 - H D H Aa d dt ot h eh y p o t h e s i st h a t
increasing the phagocytosis activity of macrophages is an
important effect of the hydroxylated anti-inflammatory and
proresolution lipid mediators derived from either AA or
DHA.
Concerning the anti-inflammatory effect of ASA, the
results presented here support additional anti-inflammatory
mechanisms of ASA as compared to the mere inhibition of
prostaglandin synthesis, by enhancing the formation of 17-
HDHA in murine colitis. Together with the established effect
of ASA in colon cancer prevention, the findings presented
h e r em i g h tt h u sb ea b l et oc o n t r i b u t et oi n t e r e s ti nac a r e f u l
reevaluationofASAtherapyinpatientswithUCwithitshigh
risk of colon cancer development, possibly in combination
with DHA supplementation.8 BioMed Research International
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Figure 5: Effect of 17-HDHA on phagocytosis and overview of DHA-derived lipid mediators. (a) Effect of 17R/S-HDHA on phagocytosis in
RAW 264.7 murine macrophages (𝑛=1 2 ,
∗𝑃 = 0.026). (b) Synthesis pathways of DHA-derived anti-inflammatory lipid mediators arising
from 17R- and 17S-HDHA, and the resulting mediators are called the resolvins D1-4. Included also are the references to the published effects
of the DHA-derived mediators on TNF-𝗼 secretion from macrophages [23, 48], phagocytosis [56], and DSS-colitis activity [23].
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